Rodman & Renshaw began coverage on shares of Indivior (NASDAQ:INDV - Free Report) in a report issued on Tuesday morning, MarketBeat Ratings reports. The brokerage issued a buy rating and a $16.00 target price on the stock.
A number of other brokerages have also issued reports on INDV. Piper Sandler reiterated an "overweight" rating and issued a $16.00 price target (up previously from $15.00) on shares of Indivior in a report on Friday, October 25th. Craig Hallum cut their target price on shares of Indivior from $20.00 to $16.00 and set a "buy" rating on the stock in a research report on Friday, October 11th.
Read Our Latest Stock Report on Indivior
Indivior Stock Performance
INDV stock traded down $0.32 on Tuesday, reaching $11.89. The company's stock had a trading volume of 333,113 shares, compared to its average volume of 1,121,261. Indivior has a 12-month low of $7.33 and a 12-month high of $23.22. The business has a fifty day simple moving average of $11.75 and a two-hundred day simple moving average of $11.02. The firm has a market cap of $1.64 billion, a PE ratio of -297.60 and a beta of 0.74.
Institutional Inflows and Outflows
A number of institutional investors have recently bought and sold shares of INDV. Mirae Asset Global Investments Co. Ltd. purchased a new stake in shares of Indivior during the 4th quarter valued at $56,000. China Universal Asset Management Co. Ltd. purchased a new stake in shares of Indivior during the 4th quarter worth about $359,000. Hennion & Walsh Asset Management Inc. acquired a new stake in Indivior during the 4th quarter worth approximately $1,192,000. Geode Capital Management LLC lifted its position in Indivior by 7.7% during the third quarter. Geode Capital Management LLC now owns 132,239 shares of the company's stock valued at $1,289,000 after buying an additional 9,500 shares in the last quarter. Finally, Public Employees Retirement System of Ohio purchased a new position in shares of Indivior in the 3rd quarter valued at $294,000. 60.33% of the stock is currently owned by institutional investors and hedge funds.
Indivior Company Profile
(
Get Free Report)
Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.
Recommended Stories
Before you consider Indivior, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Indivior wasn't on the list.
While Indivior currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
